Grant Pickering, Vaxcyte CEO
Vaxcyte unveils new data on challenger to Pfizer’s Prevnar, heads toward PhIII
Vaxcyte touted Monday morning results from a second Phase II study — this time in adults 65 and older — of its 24-valent pneumococcal vaccine, which it hopes can take on Pfizer’s 20-valent shot Prevnar 20 and cover four more serotypes.
In the Phase II study, Vaxcyte studied three different doses, and plans to take the 2.2 mcg dose to the next stage. In about 45 participants, the 2.2 mcg dose of Vaxcyte’s shot VAX-24 was just as good as Prevnar 20 in 18 of the 20 serotypes that they share. It also cleared the bar for the four serotypes that Prevnar 20 doesn’t have.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
